Foghorn Therapeutics Inc.
FHTXNASDAQHealthcare● Active
$3.71
$-0.02(-0.54%)
Market Cap$217828569
P/E Ratio—
52W High$6.95
52W Low$3.27
Foghorn Therapeutics Inc. (FHTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FHTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.29
Est. -$0.28 · -3.6%
Revenue
$0.00B
Est. $0.01B · -58.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
FHTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.24 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.28 | -$0.29 | -3.6% | $0.00B | $0.01B | -58.9% |
| ▼ Q1 FY2026 | Mar 11, 2026 | -$0.28 | -$0.34 | -21.4% | $0.01B | $0.01B | -8.9% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.31 | -$0.25 | +19.4% | $0.01B | $0.01B | -14.2% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.31 | -$0.28 | +9.7% | $0.01B | $0.01B | -7.5% |
| — Q2 FY2025 | May 14, 2025 | -$0.30 | -$0.30 | +0.0% | $0.01B | $0.01B | -4.6% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.43 | -$0.30 | +30.2% | $0.00B | $0.01B | -67.1% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.42 | -$0.31 | +26.2% | $0.01B | $0.01B | -4.0% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.29
EPS Est.
-$0.28
EPS Surpr.
-3.6%
Revenue
$0.00B
Q1 FY2026
Mar 11, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.28
EPS Surpr.
-21.4%
Revenue
$0.01B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.31
EPS Surpr.
+19.4%
Revenue
$0.01B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.31
EPS Surpr.
+9.7%
Revenue
$0.01B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
$0.01B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.43
EPS Surpr.
+30.2%
Revenue
$0.00B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
-$0.31
EPS Est.
-$0.42
EPS Surpr.
+26.2%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.44 | $-0.26 | $-0.07 | 2 |
| Q3 FY2027 | $-0.44 | $-0.26 | $-0.07 | 2 |
| Q2 FY2027 | $-0.43 | $-0.26 | $-0.06 | 2 |
| Q1 FY2027 | $-0.44 | $-0.26 | $-0.07 | 2 |
| Q4 FY2026 | $-0.40 | $-0.23 | $-0.06 | 4 |
| Q3 FY2026 | $-0.35 | $-0.25 | $-0.18 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -3.6% | $4.68 | $4.20 | -10.26% |
| ▼ Q1 FY2026 | Mar 11, 2026 | -21.4% | $5.49 | $5.65 | +2.91% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +19.4% | $3.53 | $4.00 | +13.31% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +9.7% | $5.14 | $5.00 | -2.72% |
| ▲ Q2 FY2025 | May 14, 2025 | +0.0% | $4.33 | $4.11 | -5.08% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +30.2% | $4.67 | $4.50 | -3.64% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +26.2% | $8.30 | $8.24 | -0.72% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +25.0% | $5.04 | $5.24 | +3.97% |
Q2 FY2026-10.26%
Report Date
May 7, 2026
EPS Beat/Miss
-3.6%
Price Before
$4.68
Price After
$4.20
Q1 FY2026+2.91%
Report Date
Mar 11, 2026
EPS Beat/Miss
-21.4%
Price Before
$5.49
Price After
$5.65
Q4 FY2025+13.31%
Report Date
Nov 5, 2025
EPS Beat/Miss
+19.4%
Price Before
$3.53
Price After
$4.00
Q3 FY2025-2.72%
Report Date
Aug 5, 2025
EPS Beat/Miss
+9.7%
Price Before
$5.14
Price After
$5.00
Q2 FY2025-5.08%
Report Date
May 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$4.33
Price After
$4.11
Q1 FY2025-3.64%
Report Date
Mar 6, 2025
EPS Beat/Miss
+30.2%
Price Before
$4.67
Price After
$4.50
Q4 FY2024-0.72%
Report Date
Nov 4, 2024
EPS Beat/Miss
+26.2%
Price Before
$8.30
Price After
$8.24
Q3 FY2024+3.97%
Report Date
Aug 8, 2024
EPS Beat/Miss
+25.0%
Price Before
$5.04
Price After
$5.24
Avg Beat Reaction+0.85%
Avg Miss Reaction-3.67%
Beat Rate6 / 8 quarters
Largest Move+13.31% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FHTX ends December
Foghorn Therapeutics Inc. (FHTX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.29 — missing the analyst consensus of $-0.28 by -3.6%. The next FHTX earnings date is expected around September 1, 2026.
Each quarter, investors track FHTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FHTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FHTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FHTX earnings · 5 questionsFoghorn Therapeutics Inc.'s next earnings report is expected around September 1, 2026. FHTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FHTX historically reports after market close (AMC).
FHTX earnings datewhen is FHTX earningsFHTX next earnings datewhen does FHTX report earningsFHTX earnings calendar
▸ Source: FMP · Foghorn Therapeutics Inc. SEC filings · US GAAP · Foghorn Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026